编者按：二十六届APASL年会已进入第三日，《国际肝病》记者在现场采访到一位来自蒙古肝脏疾病研究学会肝病学专家-Amarsanaa Jazag教授（Happy Veritas 肝脏诊断中心）。他向我们介绍了蒙古的病毒性肝炎发病情况，在此次会议上的发言内容，并分享参加APASL2017的感受。在采访最后，Jazag教授向广大中国同仁发出了将于今年6月在蒙古召开的APASL单主题会议的参会邀请。

 

　　《国际肝病》：蒙古的病毒性肝炎发病率非常高，你能解释一下原因吗？

 

　　<Hepatology Digest>: Mongolia has a very high incidence of viral hepatitis. Can you explain why that is?

 

　　Amarsanaa Jazag教授：乙型和丙型肝炎在蒙古的流行率很高。这始于20世纪60年代。当我们回顾文件时发现，在抗瘟疫疫苗接种以后，病毒性肝炎的发病率就变得非常高。在当时，他们不知道是哪种类型的肝炎。只知道它通过注射器的针头传播。针头和手术器械的卫生不良是导致蒙古病毒性肝炎迅速蔓延的原因。

 

　　Prof. Jazag: Hepatitis B and C have a very high prevalence in Mongolia. This started back in the 1960s. When we have looked back through documentation, we can see that after anti-plague vaccinations, there was a very high incidence of viral hepatitis. At that time, they didn’t know what kind of hepatitis it was. The only thing they knew was that it was spread by the needles used for injection. Bad sanitation of needles and surgical instruments was the cause of the rapid spread of viral hepatitis in Mongolia.

 

　　《国际肝病》：请您简要介绍一下您在APASL 2017的演讲？

 

　　<Hepatology Digest>:  Can you give us a brief introduction to your presentation here at APASL 2017?

 

　　Amarsanaa Jazag教授：在我的演讲中，我将介绍蒙古如何计划在不久的将来消除丙型肝炎病毒。我们成功地推出了针对HCV的新治疗方法，并且我们是第一个这样做的国家。随着HCV抗病毒药物的引入，我们还将让保险覆盖这些药物，所以我们的患者能够选择一个最低的价格。现在，蒙古是一个天堂，在那里患者能够以合理的价格获得治疗。

 

　　Prof. Amarsanaa: In my presentation, I will introduce how Mongolia is planning the elimination of the hepatitis C virus in the near future. We have successfully introduced the new treatments against HCV and we were the first country to do so. With the introduction of HCV antiviral drugs, we have also had them covered by insurance, so our patients have one of the lowest possible pricing choices. Right now, Mongolia is a paradise in terms of patients being able to access treatment at an affordable price.

 

　　《国际肝病》：请能谈一谈参加APASL年会的感受？

 

　　<Hepatology Digest>: What are your feelings attending this APASL Annual Meeting?

 

　　Amarsanaa Jazag教授：这是我第二次访问上海。我知道上海有非常深厚和久远的文化底蕴，我期待着更多地了解上海及其人民。除了观光以外，我也对这里的科学会议非常感兴趣。我想参加更多的关于乙型肝炎和丁型肝炎（HDV）持续发展的讲座。蒙古的乙型和丁型肝炎发病率非常高。在乙型和丁型肝炎领域有许多药物正在研发，所以非常有意思。这次大会还有许多关于肝硬化和肝细胞癌的会议，对此我想有更多更进一步的了解。

 

　　蒙古致力于成为世界上第一个成功消除丙型肝炎病毒的国家。去年我们治疗了10000名患者，这种治疗还将继续进行。我们经历了一些问题，比如患者的依从性和筛查问题，我们不知道谁有HCV，谁有HBV。对于一些人来说，这是已知的，但更多的是未知。我们希望有一个国家性的筛查计划。我们也希望医院的卫生状况得到进一步的改善，这样新发感染的传播将会受到限制。

 

　　儿童肝病是一个非常重要和关键的问题。在蒙古，我们有一个从20世纪90年代开始，针对乙型肝炎疫苗接种计划。在最近的研究中，儿童HBV的流行率显著下降。我们有新一代的儿童完全没有乙型肝炎。中国最近的发展目标是实现同样的目的，试图消除乙型和丙型肝炎病毒的垂直传播。我认为我们是其他国家的一个很好的榜样。

 

　　另外，我们准备今年6月16～18日组织一次APASL单主题会议，我想邀请我们的中国同仁来到蒙古与我们的蒙古医生和其他亚太同事进行一场意义非凡的科学讨论。他们也将在蒙古享受到蒙古美妙的风光。

 

　　Prof. Amarsanaa: This is my second time visiting Shanghai. I know Shanghai has a very deep and long culture and I look forward to knowing more about Shanghai and its people. Besides sightseeing, I am also very interested in the scientific sessions here. I want to attend more lectures here about ongoing developments in hepatitis B and hepatitis delta (HDV) as well. Mongolia has a very high incidence of hepatitis B and D. There are many drug developments going on in the area of hepatitis B and D, so it is very interesting. There are also many sessions on liver cirrhosis and hepatocellular carcinoma and I want to know more about this. Mongolia is aiming to become the first country in the world to successfully eliminate the hepatitis C virus. We treated up to 10000 patients last year and that will continue. We have experienced some problems such as patient compliance and problems with screening. We don’t know who has HCV and who has HBV. For some people it is known but for many more it is unknown. We would like to have a national screening program. We would also like to have better sanitation in hospitals so the spread of new infections is also limited.

 

　　We are organizing an APASL single topic conference for June 16-18 this year, and I would like to invite our Chinese colleagues to come to Mongolia to have a great scientific discussion with our Mongolian doctors and other Asia-Pacific colleagues. They will also enjoy the wonderful sightseeing in Mongolia.

 

　　Liver disease in children is a very important and crucial issue. In Mongolia, we have a vaccination program, which started in the 1990s, against hepatitis B. In recent studies, the prevalence of HBV in children has drastically reduced. We have a new generation of children who are free of hepatitis B. Recent developments in China are aimed at achieving the same thing. They are trying to eliminate vertical transmission of the hepatitis B and C viruses. I think we are a very good model for other countries.